MorphoSys (NASDAQ:MOR) Rating Increased to Overweight at Mor

Morgan Stanley upgraded shares of MorphoSys (NASDAQ:MOR – Free Report) from an underweight rating to an overweight rating in a report issued on Friday morning, MarketBeat Ratings reports. The firm currently has $9.20 price objective on the stock, up from their prior price objective of $3.70. MOR has been the subject of several other reports. […]

Related Keywords

United States , , Deutsche Bank Aktiengesellschaft , Virtu Financial , Jpmorgan Chase Co , Goldman Sachs Group , Wells Fargo Company , Optiver Holding , T Rowe Price Investment Management Inc , Citadel Advisors , Morgan Stanley , Free Report , Marketbeat Ratings , Get Free Report , Price Investment Management , Morphosys Daily , Morphosys , Nasdaq Mor , Humor , Medical , Upgrade ,